In 3rd Reversal, PTAB Will Eye Seagen Patent In $42M Case
Reversing itself for the third time, the Patent Trial and Appeal Board has agreed to review a Seagen cancer drug patent, finding that Daiichi Sankyo, which a Texas jury told to...To view the full article, register now.
Already a subscriber? Click here to view full article